A Comprehensive Analysis of Hungarian MODY Patients—Part I: Gene Panel Sequencing Reveals Pathogenic Mutations in HNF1A, HNF1B, HNF4A, ABCC8 and INS Genes

Zsolt Gaál 1, Zsuzsanna Szűcs 2, Irén Kántor 3, Andrea Luczay 4, Péter Tóth-Heyn 4, Orsolya Benn 5, Enikő Felszeghy 6, Zsuzsanna Karádi 5, László Madar 2 and István Balogh 2,*

1 4th Department of Medicine, Jósa András Teaching Hospital, 4400 Nyíregyháza, Hungary; dr.gaal.zsolt@skszbfk.hu
2 Division of Clinical Genetics, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; szucs.zsuzsanna@med.unideb.hu (Z.S.); madar.laszlo@med.unideb.hu (L.M.)
3 Department of Pediatrics, Jósa András Teaching Hospital, 4400 Nyíregyháza, Hungary; kantoriren@index.hu
4 1st Department of Pediatrics, Semmelweis University, 1085 Budapest, Hungary; luczay.andrea@med.ssemmelweis-univ.hu (A.L.); toth-heyn.peter@med.ssemmelweis-univ.hu (P.T.-H.)
5 Department of Pediatrics, Szent György Hospital of Fejér County, 8000 Székesfehérvár, Hungary; bennorsolya@gmail.com (O.B.); zskaradi@mail.fmkorhaz.hu (Z.K.)
6 Department of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; felszeghy.eniko@med.unideb.hu
* Correspondence: balogh@med.unideb.hu

Abstract: Maturity-onset diabetes of the young (MODY) has about a dozen known causal genes to date, the most common ones being HNF1A, HNF4A, HNF1B and GCK. The phenotype of this clinically and genetically heterogeneous form of diabetes depends on the gene in which the patient has the mutation. We have tested 450 Hungarian index patients with suspected MODY diagnosis with Sanger sequencing and next-generation sequencing and found a roughly 30% positivity rate. More than 70% of disease-causing mutations were found in the GCK gene, about 20% in the HNF1A gene and less than 10% in other MODY-causing genes. We found 8 pathogenic and 9 likely pathogenic mutations in the HNF1A gene in a total of 48 patients and family members. In the case of HNF1A-MODY, the recommended first-line treatment is low dose sulfonylurea but according to our data, the majority of our patients had been on unnecessary insulin therapy at the time of requesting their genetic testing. Our data highlights the importance of genetic testing in the diagnosis of MODY and the establishment of the MODY subtype in order to choose the most appropriate treatment.

Keywords: MODY; monogenic diabetes; HNF1A; transcription factor MODY; next-generation sequencing; NGS; Hungary

1. Introduction

In addition to the more common type 1 and 2 diabetes mellitus (DM), monogenic forms also exist. The major groups of these monogenic forms can be classified into two main categories: the transient or permanent neonatal form (NDM) presents before the age of six months whereas maturity-onset diabetes of the young (MODY) generally has an age of onset before 25 years, but there are exceptions [1,2]. Furthermore, diabetes can co-occur with several other symptoms as a form of rare diabetes-associated syndromes [3]. More than 20 causal genes have been linked to monogenic diabetes so far, the strongest evidence and highest prevalence having the transcription factors HNF1A, HNF4A, HNF1B and the GCK gene encoding the glucokinase enzyme [4].

In this article, we focus on MODY (OMIM # 606391), an autosomal dominant form of diabetes caused by heterozygous mutations in one of the MODY-associated genes resulting in beta-cell dysfunction [5]. First described in the 1970s [6,7], this form of diabetes is
clinically and genetically heterogeneous [8]. The phenotypic presentation depends on which gene harbours the disease-causing mutation, the most characteristic one being hyperglycaemia as a result of the disruption in insulin production/release processes [9]. Certain types of gene mutations can cause long-term complications, especially if left untreated, whereas others result in patients requiring only oral medication instead of insulin or no treatment at all [9].

The five major MODY criteria are: (1) age of onset before 25 years; (2) autosomal dominant pattern of inheritance; (3) not requiring insulin therapy or detectable C-peptides; (4) beta-cell dysfunction with normal insulin levels; and (5) the absence of the obesity which is generally associated with diabetes [10].

Transcription factor MODY (MODY1, MODY3 and MODY5): Whereas GCK-MODY (presented in Part II of this article) presents as a mild form of diabetes, patients with transcription factor MODY show more severe phenotypes. The most common transcription factors that cause MODY when mutated belong to the hepatocyte nuclear factor (HNF) family (HNF4A, HNF1A and HNF1B), resulting in MODY1, MODY3 and MODY5, respectively, but other causal transcription factor genes have also been described [11].

The HNF genes play an important role in liver development and function but in MODY it is their pancreatic activity that is primarily affected [11,12]. HNF1A and HNF4A mutations both cause progressive beta-cell dysfunction as they play a vital role in beta-cell development. This results in a similar clinical picture and increases the risk of later-onset complications [11]. Compared to GCK-MODY, in addition to hyperglycaemia, HNF1A- and HNF4A-MODY present with more characteristic phenotypes, such as polyuria, polydipsia and weight loss [13]. Both types might present with neonatal transient hyperinsulinaemic hypoglycaemia followed by a progressive insulin secretory defect later in life [14].

HNF1A-MODY is mainly the result of haploinsufficiency due to loss-of-function mutations [15]. The HNF1A gene has three isoforms generated from the same promoter by alternative splicing and it has three functional domains: an N-terminal dimerization domain, a DNA-binding domain and a C-terminal transactivation domain [16]. This gene is considered to be polymorphic; mutations have been described in every domain of the gene, with no mutational hot-spots [17]. To date, about 500 disease-causing small scale HNF1A mutations have been reported in the professional version of the HGMD (Human Gene Mutation Database, version 2021.1) associated with the MODY phenotype, the majority of them being missense alterations resulting in amino acid change. More than 80% of HNF1A mutations have been reported in exons 1–6 of 10, affecting all three isoforms of the gene and having a lower average age of diagnosis as compared to those who have mutations in exons 8–10. Patients with truncating HNF1A mutations generally have a younger age of onset compared to those who have a missense mutation, suggesting phenotype variability of MODY3 patients based on mutation type and location [9,18].

Mutations in HNF1A alter the expression of glucose transporter proteins and enzymes involved in glucose metabolism and also result in a decrease in the amount of insulin produced [9,19]. The presenting hyperglycaemia might be deteriorating and progressive, with a risk of developing complications in the long term similar to type 1 and 2 diabetes. Rigorous glucose control is required to prevent the development of long term complications [19,20]. HNF1A is involved in the glucose reuptake in the kidneys as well; HNF1A mutations thus result in renal glycosuria because of the low renal threshold for glucose. This usually precedes the beta-cell insulin secretion defect for years and it is not characteristic of HNF4A-MODY [17]. HNF1A-MODY has age-dependent high penetrance; almost 63% of the patients with HNF1A mutations develop symptoms by the age of 25, 93.6% by the age of 50 years, and 98.7% by the age of 75 years [21,22].

HNF4A is involved in the regulation of glucose transport and metabolism genes [23] and also regulates the expression of several proteins involved in lipid metabolism [24]. HNF4A-MODY is associated with macrosomia at birth [14].

Low dose sulphonylurea is the best first-line treatment in both MODY1 and MODY3 cases as it regulates blood glucose level, decreases glycosylated haemoglobin and prevents
future insulin dependencies [25]. However, with the progression of diabetes, some patients may require additional insulin therapy as well [19].

MODY5 is caused by mutations in the hepatocyte nuclear factor-1 beta (HNF1B) gene encoding a transcription factor involved in the early development of the pancreas, kidney, liver, lungs, gut and genitourinary tract. As a result, HNF1B-MODY patients can develop abnormalities in all of these organs in addition to hyperglycaemia [19], the symptoms of which often precede the diabetes. They can be characterized by pancreas hypoplasia resulting in beta-cell dysfunction and reduced insulin secretion [21]. About 50% of the patients present with hypomagnesaemia and hypokalaemia as well [26,27]. By the age of 45, patients usually develop renal dysfunction and about half of them progress to end-stage renal failure [19]. In contrast with HNF4A-MODY, HNF1B mutations can reduce birthweight by up to 900 g [19,28].

HNF1B loss-of-function mutations result in haploinsufficiency, which is responsible for the development of the disease. Large differences can be seen in phenotypic presentation and age of onset even in the same family. Furthermore, half of the patients with HNF1B-MODY have de novo mutations, and half of them also carry a large heterozygous deletion, which is in contrast with other types of MODY, where the mutations are mostly inherited from one of the parents and are usually a small-scale missense mutation [21].

In contrast with other MODY types, HNF1B-MODY patients do not respond to sulphonylurea, they usually require early insulin therapy and nephropathy management may also be necessary [19].

In these two accompanying papers, we describe the results of a 10-year genetic and clinical analysis of Hungarian MODY patients. Being the sole genetic centre in the country, our results represent the data of the entire Hungarian cohort of MODY.

2. Materials and Methods

2.1. Patients

A total of 450 unrelated index patients with suspected MODY diagnosis and their 202 family members have been referred to our laboratory for genetic testing from all around Hungary. All participants or their guardians gave informed consent to genetic testing according to national regulations.

2.2. Methods

Genomic DNA was isolated from peripheral blood leukocytes using the QIAamp Blood Mini kit (Qiagen GmbH, Hilden, Germany).

In the case of 102 index patients, Sanger sequencing of the GCK, HNF1A or HNF4A genes was performed using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s protocol.

Bidirectional pyrosequencing with a minimum coverage of 40× was performed on Roche GS Junior 454 pyrosequencing system (Roche 454 Life Sciences, Branford, CT, USA) in the case of 33 index patients.

We sequenced 311 index patient samples on Illumina Miseq or NextSeq 550 (Illumina, San Diego, CA, USA) sequencer systems in 2 × 150 cycle (or 2 × 250 cycle in case of the MODY MASTR kit) paired-end mode. We used 3 different library preparation methods before sequencing. The MODY MASTR kit (Multiplicom, Niel, Belgium) was used to examine 7 genes in the case of 76 index patients. A custom-made and enrichment-based DNA library preparation kit (Qiagen, GmbH, Hilden, Germany) containing 17 genes was used in the case of 164 index patients, and another custom-designed gene panel (Twist Bioscience, South San Francisco, CA, USA) was used, examining 18 genes in case of 69 and 20 genes in case of 6 index patients (Supplementary Table S1). In the case of Illumina sequenced data, data analysis was performed using the NextGene software (SoftGenetics, State College, PA, USA).

MLPA (Multiplex ligation-dependent probe amplification) was performed in the case of 32 index patients (as a single test in the case of 4 index patients and in addition to one
of the above-mentioned methods in the case of 28 index patients) using SALSA MLPA Probemix P241 MODY Mix 1 and/or SALSA MLPA Probemix P357 MODY Mix 2 (MRC Holland, Amsterdam, The Netherlands) according to the manufacturer’s protocol. The testing method(s) used in the case of every index patient is described in Supplementary Table S2.

Cascade testing was performed in 202 family members usually by targeted Sanger sequencing of the respective exon of the MODY-causing gene in which their relative had a possibly pathogenic mutation.

2.3. Variant Confirmation

All variants obtained with next-generation sequencing that were suspected to be disease-causing were validated by Sanger sequencing. Furthermore, when the amplicon’s minimum coverage was <40× in the NGS data, the respective exons were also sequenced using the Sanger method.

2.4. Variant Filtering and Interpretation

All detected variants having a MAF > 0.01 (minor allele frequency) in the gnomAD population database were filtered. The remaining variants were classified according to the ACMG standards and guidelines [29,30]. A web-based interpretation tool, Franklin (Genoox) [31] was used to assist the classification. HGMD Professional and ClinVar databases were also used in variant interpretation.

2.5. Clinical Data Collection

Clinical data of patients and family members having a ‘pathogenic’ (‘P’) or ‘likely pathogenic’ (‘LP’) mutation in one of the MODY-causing genes were collected from their application form, sent and filled out by their clinician at the time of requesting the genetic testing. The MODY Probability Calculator (https://www.diabetesgenes.org/ (accessed on 20 March 2021)) was used to calculate the probability of the patient having MODY when all information required was available and the patient was under the age of 35, as the calculator cannot be used in case of patients older than that.

3. Results

From the 450 index patients examined, 132 tested positive for a variant classified as ‘P’ or ‘LP’ in one of the MODY-causing genes with a total of 89 mutations, meaning a roughly 30% of positivity rate. More than 70% (65/89) of the mutations were found in the GCK gene (described in Part II of this article), around 20% (17/89) were found in the HNF1A gene and the remaining roughly 10% (7/89) in other MODY-causing genes (Table 1). Every mutation detected was in a heterozygous form.

Table 1. Distribution of the Pathogenic/Likely pathogenic mutations found in MODY-causing genes.

| Gene                | Number of ‘P’/‘LP’ Mutations Found |
|---------------------|------------------------------------|
| GCK                 | 65 (73.0%)                          |
| HNF1A               | 17 (19.1%)                          |
| Other MODY-causing gene 1 | 7 (7.9%)                          |

1 ABCC8, HNF1B, HNF4A, INS, KCNJ11; P: Pathogenic; LP: Likely Pathogenic.

Furthermore, 202 family members of the index patients harbouring a MODY-causing ‘P’ or ‘LP’ mutation were also examined, half of which (95/202) tested positive for a MODY-causing mutation. This means that a total of 227 patients were diagnosed with MODY in the examined cohort and given a clinically relevant molecular genetic diagnosis as well. Three-quarters (72/95) of the positively tested family members had a mutation in the GCK gene (presented in Part II of this article), around 20% (18/95) in the HNF1A gene and 5% (5/95) in other MODY-causing genes.
3.1. HNF1A Families

We have identified 17 different pathogenic (9) and likely pathogenic (8) HNF1A mutations in 30 index patients and their 18 family members, summarized in Table 2 and Figure 1. Six mutations were found in more than one apparently unrelated families, the most frequent ones being two nonsense mutations, p.Arg171* and p.Gln176*, found in 4-4 families, respectively. Two of 17 mutations (12%) are novel ones; the rest have been described in the literature previously. We found that 70% of the detected HNF1A mutations are missense mutations, with Arg-Trp change being the most frequent one (4 of 12). All but one mutation was detected in exons 1–6 of the HNF1A gene, this being in accordance with the more than 80% reported in the literature in the common part of the gene in all three isoforms. A total of 5 truncating mutations were found among the 17 mutations: 2 nonsense and 3 frameshift ones.

Clinical data of index patients and their family members that harbour an HNF1A mutation are presented in Supplementary Table S3. Obesity is not characteristic of these patients; few of them have developed any complications so far. HbA1c level data were available in 29 of 48 cases, but they should be handled with caution as generally the patients were already under treatment at the time of requesting their genetic testing. Six of the 29 patients have an HbA1c level lower than 6.1% and 23 have an elevated HbA1c level. The patients were diagnosed with diabetes at different ages, and the majority of the patients have received a proper molecular genetic diagnosis only several years later.

The recommended first-line treatment in the case of HNF1A-MODY is low dose sulphonylurea. We had information regarding treatment in the case of 35 HNF1A-MODY patients, but only 5 of them had received sulphonylurea treatment (one of which was combined with metformin) at the moment of requesting their genetic testing and 21 of them had already been on insulin therapy (Table 3), generally as of their diagnosis. This suggests that many patients do not receive proper treatment in the absence of a proper molecular genetic diagnosis. We do not have any information regarding therapy following the genetic diagnosis but according to the literature, insulin therapy can be switched to sulphonylurea treatment in these cases.
Table 2. Pathogenic (8) and Likely Pathogenic (9) mutations found in the HNF1A gene.

| Nucleotide Change | Protein Change | Exon/Intron | Function | ACMG | ACMG Evidence | ClinVar | GnomAD Alleles (MAF) | Pr/FM | Family ID | Novel/ Known | Reference |
|-------------------|----------------|-------------|----------|------|---------------|---------|----------------------|-------|-----------|-------------|-----------|
| c.2T > G          | p.Met1Arg      | exon 1      | Missense | Pathogenic | PM2 (2); PP1 (3); PS1 (3); PSV1 (2) | N/A | N/A | 22 (0.00009052) | 1/1 | F259 | Novel | [32] |
| c.142G > A        | p.Glu48Lys     | exon 1      | Missense | Likely pathogenic | PM1 (2); PM2 (2); PP1 (1); PP5 (3) | N/A | N/A | 1/0 | F234 | Known | |
| c.346G > C        | p.Ala116Pro    | exon 2      | Missense | Likely pathogenic | PM1 (2); PM2 (2); PP1 (1); PP5 (3) | Pathogenic (3) | N/A | 3/4 | F007, F012, F228 | Known | [33] |
| c.391C > T        | p.Arg131Trp    | exon 2      | Missense | Pathogenic | PM1 (2); PM2 (2); PM5 (1); PP2 (1); PP5 (3); PSV1 (4) | Pathogenic (2) | N/A | 4/3 | F095, F283, F361, F380 | Known | |
| c.460A > G        | p.Met154Val    | exon 2      | Missense | Likely pathogenic | PM1 (2); PM2 (2); PM5 (1); PP2 (1); PP5 (3) | Pathogenic (2) | 1 (0.000003978) | 1/0 | F204 | Known | [34] |
| c.475C > T        | p.Arg159Trp    | exon 2      | Missense | Pathogenic | PM2 (2); PM1 (2); PP1 (1); PP5 (3); PSV1 (4) | Pathogenic (2) | 1 (0.000003994) | 4/1 | F098, F297, F302, F394 | Known | [35] |
| c.526C > T        | p.Gln176*      | exon 2      | Missense | Pathogenic | PM1 (2); PM2 (2); PM5 (1); PP1 (1); PP5 (3); PSV1 (4) | Pathogenic (2) | N/A | 1/1 | F423 | Known | |
| c.598C > T        | p.Arg200Trp    | exon 3      | Missense | Likely pathogenic | PM1 (2); PM2 (2); PM5 (1); PP1 (1); PP5 (3) | Likely pathogenic (1) | N/A | 3/4 | F096, F366, F430 | Known | |
| c.599G > A        | p.Arg200Gln    | exon 3      | Missense | Pathogenic | PM1 (2); PM2 (2); PM5 (1); PP1 (1); PP5 (3) | Likely pathogenic (1) | 1 (0.00006572) | 2/0 | F199, F287 | Known | [37] |
| c.704A > G        | p.Glu235Gly    | exon 3      | Missense | Likely pathogenic | PM1 (2); PM2 (2); PP1 (1); PP5 (3) | Likely pathogenic (1) | N/A | 1/1 | F474 | Known | [38] |
| c.751G > A        | p.Ala251Thr    | exon 4      | Missense | Pathogenic | PM1 (2); PM2 (2); PM5 (1); PP2 (1); PP5 (3) | Pathogenic (2) | 0 | 1/0 | F452 | Known | [39] |
| c.811C > T        | p.Arg271Trp    | exon 4      | Missense | Pathogenic | PM1 (2); PM2 (2); PM5 (1); PP2 (1); PP5 (3) | Pathogenic (2) | 0 | 1/0 | F452 | Known | |
| c.872dupC         | p.Gly292Argfs*25 | exon 4 | Frameshift | Pathogenic | PM1 (2); PP1 (2); PP5 (3); PSV1 (4) | Pathogenic (8) | N/A | 1/1 | F025 | Known | [40] |
| c.1136_1137delCT  | p.Pro379Argfs*39 | exon 6 | Frameshift | Pathogenic | PM1 (2); PP1 (2); PP5 (3); PSV1 (4) | Pathogenic (1) | N/A | 1/2 | F141 | Known | [41] |
| c.1137delT        | p.Val380Serfs*4 | exon 6 | Frameshift | Pathogenic | PM2 (2); PP1 (2); PP5 (3); PSV1 (4) | Pathogenic (4) | N/A | 1/0 | F104 | Known | [40] |
| c.1340C > T       | p.Pro447Leu    | exon 7      | Missense | Likely pathogenic | PM2 (2); PP1 (2); PP5 (3); PSV1 (4) | Pathogenic (3) | 3 (0.00001204) | 3/0 | F196, F366, F430 | Known | [40] |

HNF1A reference sequence: NM_000545.5, novel mutations are shown in bold. ACMG: shows the classification of the mutation based on the ACMG guidelines; ACMG evidence: the criteria and their strength used for the ACMG classification, as follows: (1) supporting, (2) moderate, (3) strong, (4) very strong, (5) stand-alone; ClinVar: the classification of the mutation according to ClinVar, with the number of submissions in brackets; gnomAD MAF: minor allele frequency of the mutation in the gnomAD database; Pr/FM: number of probands / their family members the mutation was found in; Family ID: identification of the families the mutation was found in.
Figure 1. HNF1A mutations detected in the index patients. Novel mutations are shown in colour.
Table 3. Treatment of HNF1A-MODY patients prior to the genetic diagnosis.

| Therapy           | Number of Patients |
|-------------------|--------------------|
| Insulin           | 20                 |
| OAD-sulphonylurea | 4                  |
| OAD-metformin     | 3                  |
| OAD               | 1                  |
| Combined          | 2                  |
| Diet              | 4                  |
| No treatment      | 1                  |
| N/A               | 13                 |

OAD–metformin and sulphonylurea, OAD metformin and insulin. OAD: oral antidiabetic drug.

With family member screening, we detected additional diabetic family members in 12 families. Nine members were still presymptomatic.

3.2. Mutations in Other MODY Genes

Table 4 shows the mutations we detected in MODY-causing genes other than HNF1A or GCK. Mutations detected in the HNF1B gene are large scale deletions of four exons or the whole gene, this being in accordance with the literature data that copy number variations are characteristic of the HNF1B gene.
Table 4. Pathogenic and likely pathogenic mutations found in other MODY-causing genes.

| Gene   | Nucleotide Change | Protein Change | Exon/Intron | Function       | ACMG         | ACMG Evidence | ClinVar | GnomAD Alleles (MAF) | Pr/FM | Family ID       | Novel/Known | Reference |
|--------|-------------------|----------------|-------------|----------------|--------------|---------------|---------|----------------------|-------|-----------------|-------------|-----------|
| ABCC8  | c.643G > A        | p. Val215Ile   | exon 5      | Missense       | Likely pathogenic | PM1 (1); PM2 (2); PP1 (1); PP2 (1); PP3 (1) | N/A     | N/A                 | 1/2   | F196            | Known       | [42]      |
| ABCC8  | c.3988 + 1G > A   | Splice         | intron 32   | Splicing       | Likely pathogenic | PM2 (2); PVS1 (4) | N/A     | N/A                 | 1/0   | F305            | Novel       |          |
| HNF1B  | del e1–e4         |                |             | Pathogenic     |              |               |         |                     |       | F091, F172      | Known       |          |
| HNF1B  | del e1–e9         |                |             | Pathogenic     |              |               |         |                     |       | F076, F372, F388 | Known       |          |
| HNF4A  | c.869G > A        | p. Arg290His   | exon 8      | Missense       | Likely pathogenic | PM2 (2); PP3 (1); PFS5 (1) | Uncertain significance (2) | 1 (0.000004031) | 2/1 | F097, F192      | Known       | [45]      |
| INS    | c.128G > A        | p. Cys43Tyr    | exon 1      | Missense       | Likely pathogenic | PM1 (1); PM2 (2); PP2 (1); PP3 (1); PP5 (1) | N/A     | N/A                 | 1/0   | F284            | Novel       |          |
| KCNJ11 | c.685G > A        | p. Glu229Lys   | exon 1      | Missense       | Likely pathogenic | PM1 (1); PM2 (2); PP2 (1); PP3 (1); PP5 (1) | Pathogenic (1) | N/A                 | 1/1   | F315            | Known       | [46]      |

Reference sequences: ABCC8 NM_000352.3, HNF4A NM_000457.4, INS NM_000207.2, KCNJ11 NM_000525.3, novel mutations are shown in bold. ACMG: shows the classification of the mutation based on the ACMG guidelines; ACMG evidence: the criteria and their strength used for the ACMG classification, as follows: (1) supporting, (2) moderate, (3) strong, (4) very strong, (5) stand-alone; ClinVar: the classification of the mutation according to ClinVar, with the number of submissions in brackets; gnomAD MAF: minor allele frequency of the mutation in the gnomAD database; Pr/FM: number of probands/their family members in whom the mutation was found; Family ID: identification of the families in which the mutation was found.
Supplementary Table S4 presents the clinical data of these index patients and their family members.

4. Discussion

In our cohort examining patients from all over Hungary, 227 patients were diagnosed with MODY in about 10 years, having a 30% positivity rate, with a 20% mutation rate in the \textit{HNF1A} gene and 70% in the \textit{GCK} gene (see Table 1 in Part II of this article). Our result is roughly similar to the prevalence of \textit{GCK}-MODY and \textit{HNF1A}-MODY described in other populations in Europe. For example, a screening study in Poland reports a positivity rate of 40%, in which in 96% of the cases the \textit{GCK} gene was responsible for the MODY phenotype \cite{47}. An Italian study of children with incidental hyperglycaemia reports a 70% positivity rate, \textit{GCK\textendash}MODY being the most common with 90% \cite{48}. In Greece, the \textit{GCK\textendash}MODY ratio is reported to be somewhat lower with only 54% and \textit{HNF1A\textendash}MODY with 12% \cite{49}. A very recent Greek study puts the diagnostic rate at 20% \cite{50}. These data show that the inclusion criteria for testing, the methodology used (i.e., number of analysed genes if gene panel testing is applied and whether copy number variation analysis is performed or not) might significantly affect the pickup rate.

It is worth mentioning that we cannot exclude the MODY diagnosis of patients in which we could not detect any pathogenic or likely pathogenic mutations, as there are other MODY-causing genes which we have not tested. Moreover, these patients could have a disease-causing mutation in the intronic, regulatory or promoter region of one of the genes examined that we have not sequenced. It is also possible that they harbour a mutation that we know very little about, and it is classified as a variant of uncertain significance.

The variants found in the \textit{ABCC8} and \textit{KCNJ11} genes have been published in cases with neonatal diabetes phenotype \cite{42,46}. However, other, very similar mutations in the \textit{KCNJ11} gene, such as the p.Glu227Lys—which is located only two amino acid residues upstream to our mutation and the same missense alteration—have been previously described in both neonatal diabetes and MODY cases \cite{51}. The \textit{KCNJ11} c.685G > A, p.Glu229Lys (Family 315) is indeed very interesting as the father of the index patient carries the mutation, too, and his diabetes was diagnosed at the age of 40 years while the diabetes of the index patient was diagnosed at the age of 13, suggesting a variable expressivity of the alteration, probably affected by other genetic and/or environmental factors.

Generally, these MODY positive patients had already been diagnosed with diabetes years before their genetic testing was requested, and MODY was suspected only years later, which resulted in the incorrect treatment of several patients. In many cases, MODY patients are misclassified as having Type 1 diabetes before receiving a MODY diagnosis. All of them were on insulin treatment. According to our knowledge, most of them can be transferred to successful sulphonylurea treatment.

We would like to emphasize the importance of the molecular genetic diagnosis, which can result in a change in the therapy. Although patients with \textit{HNF1A} mutations usually need sulphonylurea treatment, having to take an oral antidiabetic drug makes their life much easier than the daily insulin injections, which cause them unnecessary discomfort in their everyday life, and improves the quality of life substantially and decreases their expenditure on treatment.

We also diagnosed family members with \textit{HNF1A\textendash}MODY before they started to show any symptoms of diabetes, some of them still being in early childhood. Their blood glucose levels should be closely monitored, and their therapy started when necessary, to prevent the development of long-term complications. We would also like to emphasize the importance of cascade testing as to identify all MODY patients in the families.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/life11080755/s1, Table S1. The list of genes examined with the different library preparation
kits; Table S2. Methods used for testing the index patients; Table S3. Clinical data of patients with HNF1A mutation; Table S4. Clinical data of patients having a mutation in other MODY-causing genes.

Author Contributions: Conceptualization of the study, I.B. and Z.G.; methodology, Z.S. and L.M.; clinical data analysis, Z.G., I.K., A.L., PT.-H., O.B., E.F. and Z.K.; writing—original draft preparation, Z.S.; writing—review and editing, all authors; funding acquisition, Z.G., I.B. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by OTKA K109076 and Ministry of National Economy, Hungary GINOP-2.3.2-15-2016-00039 (to I.B.).

Institutional Review Board Statement: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Patients gave informed written consent. The laboratory is approved by the National Public Health and Medical Officer Service (approval number: 0940250024).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest. Part of the data of this paper is being presented on the 60th National Congress of the Hungarian Society of Laboratory Medicine Online Congress, 26–28 August 2021.

References
1. Barbetti, F.; D’Annunzio, G. Genetic Causes and Treatment of Neonatal Diabetes and Early Childhood Diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 2018, 32, 575–591. [CrossRef]
2. Firdous, P.; Nissar, K.; Ali, S.; Ganai, B.A.; Shabir, U.; Hassan, T.; Masoodi, S.R. Genetic Testing of Maturity-Onset Diabetes of the Young Current Status and Future Perspectives. Front. Endocrinol. 2018, 9, 253. [CrossRef] [PubMed]
3. Alkorta-Aranburu, G.; Carmody, D.; Cheng, Y.W.; Nelakuditi, V.; Ma, L.; Dickens, J.T.; Das, S.; Greeley, S.W.; Del Gaudio, D. Phenotypic Heterogeneity in Monogenic Diabetes: The Clinical and Diagnostic Utility of a Gene Panel-Based next-Generation Sequencing Approach. Mol. Genet. Metab. 2014, 113, 315–320. [CrossRef] [PubMed]
4. Campbell, M.R. Review of Current Status of Molecular Diagnosis and Characterization of Monogenic Diabetes Mellitus: A Focus on next-Generation Sequencing. Expert Rev. Mol. Diagn. 2020, 20, 413–420. [CrossRef] [PubMed]
5. Heuvel-Borsboom, H.; de Valk, H.W.; Losekoot, M.; Westerink, J. Maturity Onset Diabetes of the Young: Seek and You Will Find. Neth. J. Med. 2016, 74, 193–200.
6. Tattersall, R.B. Mild Familial Diabetes with Dominant Inheritance. Q. J. Med. 1974, 43, 339–357.
7. Tattersall, R.B.; Fajans, S.S.; Arbor, A. A Difference between the Inheritance of Classical Juvenile-Onset and Maturity-Onset Type Diabetes of Young People. Diabetes 1975, 24, 44–53. [CrossRef]
8. Thethy, L.; Robertson, L.; Swaminathan, K. Diagnosis in Diabetes: Does It Matter? J. R. Coll. Physicians Edinb. 2011, 41, 119–121. [CrossRef]
9. Yahaya, T.O.; Ufuoma, S.B. Genetics and Pathophysiology of Maturity-Onset Diabetes of the Young (MODY): A Review of Current Trends. Oman Med. J. 2020, 35, e126. [CrossRef]
10. Vaxillaire, M.; Froguet, P. Monogenic Diabetes in the Young, Pharmacogenetics and Relevance to Multifactorial Forms of Type 2 Diabetes. Endocr. Rev. 2008, 29, 254–264. [CrossRef] [PubMed]
11. Molven, A.; Njolstad, P.R. Role of Molecular Genetics in Transforming Diagnosis of Diabetes Mellitus. Expert Rev. Mol. Diagn. 2011, 11, 313–320. [CrossRef]
12. Boj, S.F.; Parrrizas, M.; Maestro, M.A.; Ferrer, J. A Transcription Factor Regulatory Circuit in Differentiated Pancreatic Cells. Proc. Natl. Acad. Sci. USA 2001, 98, 14481–14486. [CrossRef] [PubMed]
13. Chambers, C.; Fouts, A.; Dong, F.; Colclough, K.; Wang, Z.; Batish, S.D.; Jaremko, M.; Ellard, S.; Hattersley, A.T.; Klingensmith, G.; et al. Characteristics of Maturity Onset Diabetes of the Young in a Large Diabetes Center. Pediatr. Diabetes 2016, 17, 360–367. [CrossRef] [PubMed]
14. Karaoglan, M.; Nacarkahya, G. Clinical and Laboratory Clues of Maturity-Onset Diabetes of the Young and Determination of Association with Molecular Diagnosis. J. Diabetes 2020, 13, 154–163. [CrossRef] [PubMed]
15. Ferrer, J. A Genetic Switch in Pancreatic β-Cells: Implications for Differentiation and Haploinsufficiency. Diabetes 2002, 51, 2355–2362. [CrossRef] [PubMed]
16. Bellanne-Chaulet, C.; Carette, C.; Riveline, J.-P.; Valéro, R.; Gautier, J.-F.; Larget, E.; Reznik, Y.; Ducluzeau, P.-H.; Sola, A.; Hartemann-Heurtier, A.; et al. The Type and the Position of HNF1A Mutation Modulate Age at Diagnosis of Diabetes in Patients with Maturity-Onset Diabetes of the Young (MODY)-3. Diabetes 2008, 57, 503–508. [CrossRef]
17. Valkovicova, T.; Skopkova, M.; Stanik, J.; Gasperikova, D. Novel Insights into Genetics and Clinics of the HNF1A-MODY. Endocr. Regul. 2019, 53, 110–134. [CrossRef] [PubMed]

18. Ellard, S.; Bellanné-Chantelot, C.; Hattersley, A.T. European Molecular Genetics Quality Network (EMQN) MODY group Best Practice Guidelines for the Molecular Genetic Diagnosis of Maturity-Onset Diabetes of the Young. Diabetologia 2008, 51, 546–553. [CrossRef]

19. Jang, K.M. Maturity-Onset Diabetes of the Young: Update and Perspectives on Diagnosis and Treatment. Yenngam Unio. J. Med. 2020, 37, 13–21. [CrossRef]

20. Steele, A.M.; Shields, B.M.; Shepherd, M.; Ellard, S.; Hattersley, A.T.; Pearson, E.R. Increased All-Cause and Cardiovascular Mortality in Monogenic Diabetes as a Result of Mutations in the HNF1A Gene. Diabet. Med. 2010, 27, 157–161. [CrossRef] [PubMed]

21. Gaál, Z.; Balogh, I. Monogenic Forms of Diabetes Mellitus. Exp. Suppl. 2019, 111, 385–416. [CrossRef] [PubMed]

22. Shepherd, M.; Ellis, I.; Ahmad, A.M.; Todd, P.J.; Bowen-Jones, D.; Mannion, G.; Ellard, S.; Sparkes, A.C.; Hattersley, A.T. Predictive Genetic Testing in Maturity-Onset Diabetes of the Young (MODY). Diabet. Med. 2001, 18, 417–421. [CrossRef]

23. Stoffel, M.; Duncan, S.A. The Maturity-Onset Diabetes of the Young (MODY1) Transcription Factor HNF4α Regulates Expression of Genes Required for Glucose Transport and Metabolism. Proc. Natl. Acad. Sci. USA 1997, 94, 13209–13214. [CrossRef] [PubMed]

24. Yamagata, K. Regulation of Pancreatic β-Cell Function by the HNF Transcription Network: Lessons from Maturity-Onset Diabetes of the Young (MODY). Endocr. J. 2003, 50, 491–499. [CrossRef] [PubMed]

25. Bacon, S.; Kiyihar, M.P.; Rizvi, S.R.; Donnelly, E.; McCarthy, A.; Burke, M.; Colecough, K.; Ellard, S.; Byrne, M.M. Successful Maintenance on Sulphonylurea Therapy and Low Diabetes Complication Rates in a HNF1A-MODY Cohort. Diabet. Med. J. Br. Diabet. Assoc. 2015, 33, 976–984. [CrossRef]

26. Adalat, S.; Woolf, A.S.; Johnstone, K.A.; Wirsing, A.; Harries, L.W.; Long, D.A.; Hennekam, R.C.; Ledermann, S.E.; Rees, L.; van’t Hoff, W.; et al. HNF1B Mutations Associate with Hypomagnesemia and Renal Magnesium Wasting. J. Am. Soc. Nephrol. 2009, 20, 1123–1131. [CrossRef]

27. Faguer, S.; Chassaing, N.; Bandin, F.; Prouheze, C.; Garnier, A.; Casemayou, A.; Huart, A.; Schanstra, J.P.; Calvas, P.; Decramer, S.; et al. The HNF1B Score Is a Simple Tool to Select Patients for HNF1B Gene Analysis. Kidney Int. 2014, 86, 1007–1015. [CrossRef] [PubMed]

28. Edghill, E.L.; Bingham, C.; Slingerland, A.S.; Minton, J.L.; Noordam, C.; Ellard, S.; Hattersley, A.T. Hepatocyte Nuclear Factor-1 Beta Mutations Cause Neonatal Diabetes and Intrauterine Growth Retardation: Support for a Critical Role of HNF-1β in Human Pancreatic Development. Diabet. Med. 2006, 23, 1301–1306. [CrossRef]

29. Richards, C.S.; Bale, S.; Bellissimo, D.B.; Das, S.; Grody, W.W.; Hegde, M.R.; Lyon, E.; Ward, B.E. Molecular Subcommittee of the ACMG Laboratory Quality Assurance Committee ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations: Revisions 2007. Genet. Med. Off. J. Am. Coll. Med. Genet. 2008, 10, 294–300. [CrossRef]

30. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–423. [CrossRef]

31. Einhorn, Y.; Einhorn, M.; Kamshov, A.; Lev, O.; Trabelsi, A.; Paz-Yaakov, N.; Gross, S.J. Gene-Specific Artificial Intelligence-Based Variant Classification Engine: Results of a Time-Capsule Experiment. Res. Sq. 2019. Available online: https://europepmc.org/article/ppr/ppr137511 (accessed on 25 February 2021).

32. Møller, A.M.; Dalgaard, L.T.; Pociot, F.; Nerup, J.; Hansen, T.; Pedersen, O. Mutations in the Hepatocyte Nuclear Factor-1alpha Gene in Chinese Maturity-Onset Diabetes of the Young in the UK. Diabetes 2003, 52, 1109–1115. [CrossRef] [PubMed]

33. Vaxillaire, M.; Rouard, M.; Yamagata, K.; Oda, N.; Kaisaki, P.J.; Boriraj, V.V.; Chevre, J.C.; Boccio, V.; Cox, R.D.; Lathrop, G.M.; et al. Identification of Nine Novel Mutations in the Hepatocyte Nuclear Factor 1 Alpha Gene Associated with Maturity-Onset Diabetes of the Young. Proc. Natl. Acad. Sci. USA 2003, 100, 13209–13214. [CrossRef] [PubMed]

34. Chan, V.; Zhang, W.Y.; Wat, N.M.S.; Lam, K.S.L. Mutations in the Hepatocyte Nuclear Factor-Ialpha Gene in Chinese MODY Families: Prevalence and Functional Analysis. Diabetologia 2002, 45, 744–746. [CrossRef]

35. Hattersley, A.T. Maturity-Onset Diabetes of the Young: Clinical Heterogeneity Explained by Genetic Heterogeneity. Diabet. J. Br. Diabet. Assoc. 1998, 15, 15–24. [CrossRef]

36. Galán, M.; García-Herrero, C.-M.; Azriel, S.; Gargallo, M.; Durán, M.; Gorgojo, J.-J.; Andia, V.-M.; Navas, M.-A. Differential Effects of HNF-1α Mutations Associated with Familial Young-Onset Diabetes on Target Gene Regulation. Mol. Med. Camb. Mass 2011, 17, 256–265. [CrossRef]

37. Thanabalasingham, G.; Huffman, J.E.; Kattla, J.J.; Novokmet, M.; Rudan, I.; Gloyin, A.L.; Hayward, C.; Adamczyk, B.; Reynolds, R.M.; Muzinic, A.; et al. Mutations in HNF1A Result in Marked Alterations of Plasma Glycan Profile. Diabetes 2013, 62, 1329–1337. [CrossRef]

[CrossRef]

[PubMed]
40. Yamagata, K.; Oda, N.; Kaisaki, P.J.; Menzel, S.; Furuta, H.; Vaxillaire, M.; Southam, L.; Cox, R.D.; Lathrop, G.M.; Boriraj, V.V.; et al. Mutations in the Hepatocyte Nuclear Factor-1alpha Gene in Maturity-Onset Diabetes of the Young (MODY3). *Nature* **1996**, *384*, 455–458. [CrossRef]  
41. Hansen, T.; Eiberg, H.; Rouard, M.; Vaxillaire, M.; Moller, A.M.; Rasmussen, S.K.; Fridberg, M.; Urhammer, S.A.; Holst, J.J.; Almind, K.; et al. Novel MODY3 Mutations in the Hepatocyte Nuclear Factor-1alpha Gene: Evidence for a Hyperexcitability of Pancreatic Beta-Cells to Intravenous Secretagogues in a Glucose-Tolerant Carrier of a P447L Mutation. *Diabetes* **1997**, *46*, 726–730. [CrossRef]  
42. Rafiq, M.; Flanagan, S.E.; Patch, A.-M.; Shields, B.M.; Ellard, S.; Hattersley, A.T. Neonatal Diabetes International Collaborative Group Effective Treatment with Oral Sulfonylureas in Patients with Diabetes Due to Sulfonylurea Receptor 1 (SUR1) Mutations. *Diabetes Care* **2008**, *31*, 204–209. [CrossRef]  
43. Yorifuji, T.; Fujimaru, R.; Hosokawa, Y.; Tamagawa, N.; Shiozaki, M.; Aizu, K.; Jinno, K.; Maruo, Y.; Nagasaka, H.; Tajima, T.; et al. Comprehensive Molecular Analysis of Japanese Patients with Pediatric-Onset MODY-Type Diabetes Mellitus. *Pediatr. Diabetes* **2012**, *13*, 26–32. [CrossRef]  
44. Le Berre, J.-P.; Bellanné-Chantelot, C.; Bordier, L.; Garcia, C.; Dupuy, O.; Mayaudon, H.; Bauduceau, B. Type 2 diabetes mellitus associated with pancreatic and renal malformations. *Rev. Med. Interne* **2010**, *31*, e5–e6. [CrossRef]  
45. Jermendy, G.; Balogh, I.; Gaál, Z. HNF-4-α-mutáció okozta monogén diabetes mellitus (MODY-1) első hazai esete. *Orv. Hetil.* **2016**, *157*, 469–473. [CrossRef]  
46. Girard, C.A.J.; Shimomura, K.; Proks, P.; Absalom, P.; Castano, L.; Perez de Nanclares, G.; Ashcroft, F.M. Functional Analysis of Six Kir6.2 (KCNJ11) Mutations Causing Neonatal Diabetes. *Pflugers Arch.* **2006**, *453*, 323–332. [CrossRef]  
47. Malachowska, B.; Borowiec, M.; Antosik, K.; Michalak, A.; Baranowska-Jaźwiecka, A.; Deja, G.; Jarosz-Chobot, P.; Brandt, A.; Myśliwiec, M.; Stelmach, M.; et al. Monogenic Diabetes Prevalence among Polish Children—Summary of 11 Years-Long Nationwide Genetic Screening Program. *Pediatr. Diabetes* **2018**, *19*, 53–58. [CrossRef]  
48. Lorini, R.; Klersy, C.; d'Annunzio, G.; Massa, O.; Minuto, N.; Iafusco, D.; Bellanné-Chantelot, C.; Frongia, A.P.; Toni, S.; Meschi, F.; et al. Maturity-Onset Diabetes of the Young in Children with Incidental Hyperglycemia: A Multicenter Italian Study of 172 Families. *Diabetes Care* **2009**, *32*, 1864–1866. [CrossRef]  
49. Tatsi, E.B.; Kanaka-Gantenbein, C.; Scorilas, A.; Chrósoos, G.P.; Sertedaki, A. The Spectrum of HNF1A Gene Mutations in Greek Patients with MODY3: Relative Frequency and Identification of Seven Novel Germline Mutations. *Pediatr. Diabetes* **2013**, *14*, 526–534. [CrossRef]  
50. Tatsi, E.B.; Kanaka-Gantenbein, C.; Scorilas, A.; Chrósoos, G.P.; Sertedaki, A. Next Generation Sequencing Targeted Gene Panel in Greek MODY Patients Increases Diagnostic Accuracy. *Pediatr. Diabetes* **2020**, *21*, 28–39. [CrossRef]  
51. Bonnefond, A.; Philippe, J.; Durand, E.; Dechaume, A.; Huyvaert, M.; Montagné, L.; Marre, M.; Balkau, B.; Fajardy, I.; Vambergue, A.; et al. Whole-Exome Sequencing and High Throughput Genotyping Identified KCNJ11 as the Thirteenth MODY Gene. *PLoS ONE* **2012**, *7*, e37423. [CrossRef]